Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Three-gene immune risk score study for neoadjuvant chemoimmunotherapy benefit in resectable locally advanced oral cancer
ChiCTR2400091891Phase 2Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of paclitaxel and cisplatin in mouth cancer and head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Pathologic response and Objective response rate. Started Nov 2024; status: recruiting.
02
Drugs
paclitaxelcisplatin
03
Conditions
mouth cancerhead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2400091891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091891.